DCPH vs. AGIO, FPRX, SNDX, XNCR, ALXO, ROIV, ELAN, INSM, ASND, and LEGN
Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Agios Pharmaceuticals (AGIO), Five Prime Therapeutics (FPRX), Syndax Pharmaceuticals (SNDX), Xencor (XNCR), ALX Oncology (ALXO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Insmed (INSM), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Agios Pharmaceuticals (NASDAQ:AGIO) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.
Deciphera Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Agios Pharmaceuticals had 18 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 23 mentions for Agios Pharmaceuticals and 5 mentions for Deciphera Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.09 beat Deciphera Pharmaceuticals' score of 0.24 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the news media.
71.0% of Deciphera Pharmaceuticals shares are owned by institutional investors. 4.9% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Agios Pharmaceuticals presently has a consensus target price of $35.00, suggesting a potential downside of 3.69%. Deciphera Pharmaceuticals has a consensus target price of $24.17, suggesting a potential downside of 5.36%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Agios Pharmaceuticals is more favorable than Deciphera Pharmaceuticals.
Agios Pharmaceuticals received 158 more outperform votes than Deciphera Pharmaceuticals when rated by MarketBeat users. Likewise, 67.51% of users gave Agios Pharmaceuticals an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
Deciphera Pharmaceuticals has a net margin of -108.86% compared to Deciphera Pharmaceuticals' net margin of -1,199.26%. Deciphera Pharmaceuticals' return on equity of -41.41% beat Agios Pharmaceuticals' return on equity.
Agios Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500.
Summary
Agios Pharmaceuticals beats Deciphera Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Deciphera Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Deciphera Pharmaceuticals Competitors List
Related Companies and Tools
